Skip to main content
Clinical Trials/KCT0007137
KCT0007137Recruiting未知

Therapeutic effect of surgical debulking of metastatic lymph nodes in cervical cancer stage IIICr: A phase III, randomized controlled clinical trial (DEBULK trial)

CHA University Ilsan Medical Center0 sites234 target enrollmentStarted: TBDLast updated:
Conditions

Trial Snapshot

Phase
未知
Status
Recruiting
Sponsor
Enrollment
234

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional Study

Eligibility Criteria

Ages
18(Year) to 70(Year) (—)
Sex
Female

Inclusion Criteria

  • (1) Women =20 years and = 70 years of age
  • (2) Newly diagnosed squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma
  • (3) When the radiology examinations such as CT, MRI, or PET-CT show the short-axis of the pelvic LN or paraaortic LN under the renal vein is = 2cm, or more than 3 LNs with a short axis = 1 cm
  • (4) When CCRT is planned as a treatment for cervical cancer
  • (5) A patient whose competency is ECOG performance score 0-1
  • (6) A patient which has signed the approved informed consent form for study subjects
  • (7) A patient for which it is determined that surgical debulking is possible for LN metastasis as confirmed by radiological examination

Exclusion Criteria

  • (1) A patient who has been diagnosed with cancer of any organ other than thyroid cancer (excluding stage 0 cancer) within the previous 5 years
  • (2)A patient that is pregnant or plans to become pregnant during the clinical study period
  • (3)A patient with any active infectious disease or incurable severe inflammation.
  • (4)When surgery is not possible due to internal or surgical disease
  • (5)When chemotherapy is impossible due to internal or surgical disease
  • (6)A patient with a history of pelvic radiation therapy
  • (7)A patient with a history of subtotal hysterectomy
  • (8)A patient with a remote metastasis other than a pelvic lymph node or paraaortic lymph node (Ex. Lung, subclavian lymph node, inguinal lymph node)

Investigators

Sponsor
CHA University Ilsan Medical Center

Similar Trials